Show simple item record

dc.contributor.authorBoz, C.
dc.contributor.authorOzakbas, S.
dc.contributor.authorTerzi, M.
dc.contributor.authorTurkoglu, R.
dc.contributor.authorAkman, G.
dc.contributor.authorEfendi, H.
dc.contributor.authorAltunrende, B.
dc.date.accessioned2020-06-21T13:18:02Z
dc.date.available2020-06-21T13:18:02Z
dc.date.issued2017
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.urihttps://hdl.handle.net/20.500.12712/12183
dc.description7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCEen_US
dc.descriptionDEMIRKIRAN, Meltem/0000-0002-4649-5315; Turkoglu, Recai/0000-0001-9724-851X; Altintas, Ayse/0000-0002-8524-5087; AKCALI, Aylin/0000-0002-3614-1046;en_US
dc.descriptionWOS: 000413730202068en_US
dc.description.abstracten_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipMerckMerck & Company; NovartisNovartis; Bayer-ScheringBayer AG; Tevaen_US
dc.description.sponsorshipMurat Terzi received travel grants from Merck, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis.en_US
dc.language.isoengen_US
dc.publisherSage Publications Ltden_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleReal world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosisen_US
dc.typeconferenceObjecten_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume23en_US
dc.identifier.startpage327en_US
dc.identifier.endpage328en_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record